Tumor immunotherapy has now shown its promise for many, its disappointments and failings for others. Going forward, brain tumor patients can both benefit and contribute.Tumor immunotherapy is steadily progressing. As experience accumulates, it is important to consider its generality. The reviews herein emphasize the brain’s place among other tumor sites. Two major topics are addressed.THE SITE: WHAT CAN WE EXPECT FROM IMMUNOTHERAPY WHEN THE TARGET IS IN THE BRAIN?Experience with immunotherapy for different targets in the brain, including tumor and also pathogens, is reviewed. Long-standing assumptions are confronted. The potential for beneficial responses is stressed.BRAIN TUMOR IMMUNOTHERAPY: WHAT HAVE WE LEARNED SO FAR?Clinical experience with brain tumor immunotherapy, from a variety of centers, is reviewed. Primary tumors, emphasizing glioblastoma, and brain metastases are each considered.

This book is included in DOAB.